{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":24,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":24,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"cbefac99ba71","filters":{"venue":"Cancer Communications"}},"results":[{"id":"W3208045032","doi":"10.1002/cac2.12218","title":"The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma","year":2021,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":401,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"","keywords":"Nasopharyngeal carcinoma; Medicine; Clinical Oncology; Internal medicine; Oncology; Incidence (geometry); Medical physics; Intensive care medicine; Radiation therapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.4629509190193338,"gpt":0.5729864008573355,"spread":0.1100354818380018,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007045293,0.00009930283,0.0006520771,0.000007437153,0.000346164,0.000004700078,0.0002434228,0.00008874028,0.00001382845],"category_scores_gemma":[0.001085602,0.00004959794,0.000424729,0.0001471045,0.0009398438,0.00001791966,0.0002019467,0.0001400755,3.633883e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005827668,"about_ca_system_score_gemma":0.0009248604,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004194211,"about_ca_topic_score_gemma":0.002660885,"domain_scores_codex":[0.9984654,0.000195949,0.0009630368,0.0001602323,0.00009265255,0.0001227147],"domain_scores_gemma":[0.9898243,0.007759516,0.0002678322,0.001181792,0.0008987881,0.00006774845],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001369824,0.0005111389,0.6024754,0.00003462456,0.0006378973,3.684856e-7,0.0007850295,0.00000110961,0.00002642899,0.0002399535,0.02417026,0.3709808],"study_design_scores_gemma":[0.002526346,0.0008030322,0.550494,0.00005782214,0.0004401926,0.000003206131,0.001065665,0.001066286,0.0001193642,0.0000745679,0.4433028,0.00004680846],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.4552868,0.2948679,0.00004104206,0.2474819,0.0005100695,0.0008123142,0.0001499891,0.00001321559,0.0008367273],"genre_scores_gemma":[0.5388995,0.4551938,0.003475696,0.001155559,0.000307,0.0006866923,0.00001376297,0.000008688786,0.0002593422],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4191325,"threshold_uncertainty_score":0.3462894,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4402131379","doi":"10.1002/cac2.12604","title":"Perioperative toripalimab plus neoadjuvant chemotherapy might improve outcomes in resectable esophageal cancer: an interim analysis of a phase III randomized clinical trial","year":2024,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":41,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Engineering Link (Canada)","funders":"Wu Jieping Medical Foundation; National Natural Science Foundation of China","keywords":"Medicine; Interim analysis; Internal medicine; Clinical endpoint; Hazard ratio; Oncology; Chemotherapy; Neoadjuvant therapy; Perioperative; Esophageal cancer; Adverse effect; Randomized controlled trial; Cancer; Surgery; Confidence interval; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.1068187948094256,"gpt":0.512525384030229,"spread":0.4057065892208033,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001450482,0.0002625999,0.002026272,0.000537236,0.0001282427,0.00007614869,0.0005706431,0.0001287326,0.0009315691],"category_scores_gemma":[0.0002164829,0.0001911491,0.0007337198,0.001242839,0.0005705518,0.0002154138,0.0001657607,0.0006228066,0.000004324565],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001044845,"about_ca_system_score_gemma":0.001729591,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0136622,"about_ca_topic_score_gemma":0.01163416,"domain_scores_codex":[0.9966837,0.0008780733,0.001221819,0.0004966604,0.0003648122,0.0003549622],"domain_scores_gemma":[0.9966915,0.000906485,0.0001909204,0.001682272,0.000264574,0.0002642674],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8288866,0.006155162,0.007287693,0.0001904086,0.02003483,0.0001206873,0.01504886,0.0001186537,0.00095527,0.002503153,0.0002705379,0.1184281],"study_design_scores_gemma":[0.9056875,0.002442019,0.00168128,0.0002798162,0.003643741,0.000001773352,0.0005761709,0.08266385,0.001117007,0.0000641372,0.001598043,0.0002446672],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8609058,0.1186877,0.0004475824,0.01101179,0.0008008736,0.005706212,0.0009739501,0.0001350648,0.001331005],"genre_scores_gemma":[0.9712703,0.02156721,0.0006356499,0.0002778032,0.0001733817,0.003753733,0.0002769007,0.00003573415,0.002009308],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1181835,"threshold_uncertainty_score":0.9999817,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3214235689","doi":"10.1002/cac2.12236","title":"Detection of pancreatic cancer by indocyanine green‐assisted fluorescence imaging in the first and second near‐infrared windows","year":2021,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Nanoplatforms for cancer theranostics","field":"Engineering","cited_by":28,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Saskatchewan","funders":"National Institute on Alcohol Abuse and Alcoholism; National Institutes of Health","keywords":"Indocyanine green; Pancreatic cancer; Infrared; Fluorescence; Fluorescence-lifetime imaging microscopy; Medicine; Nuclear medicine; Cancer; Chemistry; Pathology; Optics; Internal medicine; Physics","retraction":null,"screen_n_in":null,"score":{"opus":0.01768173778084683,"gpt":0.2374118677362684,"spread":0.2197301299554215,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0001239482,0.0003229704,0.0004419401,0.0001260117,0.0002210377,0.0001019164,0.001075169,0.000261792,0.0001252882],"category_scores_gemma":[0.00002413556,0.0003035256,0.00008412473,0.0005928047,0.0003071599,0.0001890604,0.0001650854,0.001504027,0.000002239414],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004337546,"about_ca_system_score_gemma":0.0001500842,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002235418,"about_ca_topic_score_gemma":0.009617197,"domain_scores_codex":[0.9985951,0.00007968411,0.000522274,0.0002458502,0.0002337012,0.0003234084],"domain_scores_gemma":[0.9975765,0.0003745938,0.000191308,0.001703262,0.000120593,0.00003375193],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004865067,0.0001194508,0.01242886,0.004406255,0.0009921592,0.00006417629,0.009078455,0.000964063,0.1187815,0.00001488763,0.7549877,0.09811393],"study_design_scores_gemma":[0.0008212971,0.00001611716,0.004201986,0.001079028,0.000244462,0.00002573995,0.0001940243,0.00973366,0.003878897,0.00007028623,0.9792007,0.0005337599],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.07813386,0.5296486,0.001256813,0.3686723,0.002733384,0.005247145,0.007725202,0.0007669727,0.005815726],"genre_scores_gemma":[0.7999282,0.07748468,0.001935922,0.1086163,0.001291074,0.005750058,0.002424957,0.0006186258,0.00195011],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.7217944,"threshold_uncertainty_score":0.9999417,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2981537896","doi":"10.1186/s40880-019-0398-0","title":"Optimal sequencing of chemotherapy with chemoradiotherapy based on TNM stage classification and EBV DNA in locoregionally advanced nasopharyngeal carcinoma","year":2019,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Head and Neck Cancer Studies","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Natural Science Foundation of China; Varian Medical Systems; Sanofi; National Key Research and Development Program of China; AstraZeneca","keywords":"Nasopharyngeal carcinoma; Stage (stratigraphy); Chemoradiotherapy; Oncology; DNA sequencing; Chemotherapy; Medicine; Internal medicine; DNA; Biology; Radiation therapy; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.05932965691010148,"gpt":0.3246480382394215,"spread":0.26531838132932,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000137468,0.0003486976,0.0008994713,0.0002730235,0.00009979888,0.00001409442,0.0004257161,0.0002909073,0.00005896418],"category_scores_gemma":[0.00001576862,0.0003043009,0.00008877493,0.0003366031,0.0004187986,0.00007472195,0.00004601299,0.001116325,0.000002134189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008321495,"about_ca_system_score_gemma":0.001247064,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002583714,"about_ca_topic_score_gemma":0.0001760955,"domain_scores_codex":[0.9983851,0.0001011626,0.0004228397,0.0004537736,0.0003457239,0.0002913481],"domain_scores_gemma":[0.9972491,0.000320033,0.00035228,0.001795657,0.0002301276,0.00005286091],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01256536,0.002017281,0.350443,0.01211328,0.0023973,0.0003110469,0.01713882,0.004886051,0.0719339,0.0009080093,0.4448493,0.0804367],"study_design_scores_gemma":[0.0188999,0.002398684,0.1806402,0.005893317,0.0002852567,0.00002680988,0.0007401787,0.02431206,0.002911557,0.00001309058,0.7626125,0.001266552],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.2256441,0.009301923,0.0001406933,0.7565109,0.0001250441,0.002439002,0.0003361448,0.00007921519,0.00542308],"genre_scores_gemma":[0.6239938,0.01340008,0.009620923,0.3481151,0.0004562945,0.00121252,0.0008699386,0.000199336,0.002131924],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.4083957,"threshold_uncertainty_score":0.9999409,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3199261654","doi":"10.1002/cac2.12205","title":"Novel strategy for disease risk prediction incorporating predicted gene expression and DNA methylation data: a multi‐phased study of prostate cancer","year":2021,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Division of Cancer Epidemiology and Genetics, National Cancer Institute; National Cancer Institute; National Institute on Aging; Swedish Cancer Foundation; Medical Research Council; Canadian Institutes of Health Research; Ovarian Cancer Research Fund; National Institutes of Health; National Heart, Lung, and Blood Institute; Vetenskapsrådet; National Health and Medical Research Council; Cancer Research UK; Wellcome Trust; European Commission; Breast Cancer Research Foundation; U.S. Department of Defense","keywords":"DNA methylation; Prostate cancer; Computational biology; Biobank; Bioinformatics; Computer science; Oncology; Medicine; Biology; Cancer; Internal medicine; Gene; Gene expression; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.09813911593421933,"gpt":0.3754635667036976,"spread":0.2773244507694783,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002542915,0.0001146514,0.0001326635,0.00003556514,0.0002580156,0.00002858025,0.0002720234,0.00006914599,0.000002889406],"category_scores_gemma":[0.0001969026,0.0001180033,0.00002703118,0.0001413347,0.00006995581,0.00002128327,0.0002951846,0.00008464894,4.233651e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002059786,"about_ca_system_score_gemma":0.0002876069,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002460729,"about_ca_topic_score_gemma":0.001141961,"domain_scores_codex":[0.9989067,0.0001663246,0.0003479129,0.0003695991,0.0001059415,0.0001035751],"domain_scores_gemma":[0.9977268,0.00005340251,0.0003354399,0.001368706,0.0004353536,0.00008031403],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00008744931,0.0004765093,0.05157971,0.00003975354,0.00007878984,8.028337e-8,0.0002692527,0.00373748,0.9373682,0.000005017114,0.00002019175,0.006337563],"study_design_scores_gemma":[0.005527282,0.0004050984,0.1869483,0.0001200534,0.0004920212,4.312592e-7,0.001138846,0.07440856,0.7282852,0.0001679282,0.002188127,0.0003181931],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9254925,0.01511828,0.05314843,0.00009766092,0.00007681948,0.0008842071,0.005157365,0.00001390292,0.00001085842],"genre_scores_gemma":[0.9760715,0.006229301,0.01293327,0.00000937694,0.00007594482,0.0005765248,0.004039766,0.00002117531,0.00004314057],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.209083,"threshold_uncertainty_score":0.4812034,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4308187251","doi":"10.1002/cac2.12383","title":"Multiplexed imaging of tumor immune microenvironmental markers in locally advanced or metastatic non‐small‐cell lung cancer characterizes the features of response to PD‐1 blockade plus chemotherapy","year":2022,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Emergent BioSolutions (Canada)","funders":"Science and Technology Commission of Shanghai Municipality; Shanghai Pulmonary Hospital; National Natural Science Foundation of China","keywords":"Chemotherapy; Oncology; Lung cancer; Medicine; Immune system; Immunotherapy; Internal medicine; CD68; Predictive marker; PD-L1; CD8; Blockade; Immune checkpoint; Cancer research; Cancer; Immunology; Immunohistochemistry; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.01455436880275003,"gpt":0.2962930912548511,"spread":0.2817387224521011,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006066286,0.000232252,0.0005078071,0.0001808131,0.0002565834,0.00001208928,0.0009706606,0.00002242545,0.0006919777],"category_scores_gemma":[0.00003799414,0.0001852557,0.0001819647,0.0006748911,0.0003593656,0.00006374046,0.0003884756,0.0004012643,6.587836e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009005233,"about_ca_system_score_gemma":0.0007210925,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002923928,"about_ca_topic_score_gemma":0.0007872672,"domain_scores_codex":[0.9981175,0.0003818948,0.0006638998,0.0002707131,0.0002677622,0.0002982006],"domain_scores_gemma":[0.9975594,0.0004023418,0.0004185732,0.001490258,0.000061431,0.0000679994],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.03554754,0.0003453599,0.005179279,0.0001209585,0.0002402194,0.000005969703,0.004818486,0.0005172539,0.9410909,0.000001122457,0.0003865605,0.01174631],"study_design_scores_gemma":[0.02228702,0.0006458776,0.659757,0.001025627,0.0003987108,0.00006461614,0.01604332,0.003147989,0.2660957,0.000003404685,0.02995607,0.0005746665],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9561726,0.02889191,0.00002624739,0.01222543,0.0001320123,0.002058924,0.0004010088,0.00001959851,0.00007224858],"genre_scores_gemma":[0.9854173,0.006349718,0.003183087,0.002031569,0.00001504442,0.001987436,0.00004992183,0.00005526919,0.0009106345],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6749952,"threshold_uncertainty_score":0.7576671,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379507891","doi":"10.1002/cac2.12447","title":"Predictive power of tertiary lymphoid structure signature for neoadjuvant chemotherapy response and immunotherapy benefit in HER2‐negative breast cancer","year":2023,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Nautical Research Society","funders":"Ligue Contre le Cancer","keywords":"Oncology; Medicine; Internal medicine; Breast cancer; Pembrolizumab; Cancer; Predictive marker; Immunotherapy; Gene signature; Biology; Gene expression","retraction":null,"screen_n_in":null,"score":{"opus":0.0151065744381033,"gpt":0.3030426649719141,"spread":0.2879360905338108,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003172308,0.000549862,0.0009669085,0.0003860776,0.000183922,0.00003403037,0.0007647692,0.001018665,0.0004855844],"category_scores_gemma":[0.00003909407,0.0004896055,0.0003138608,0.0006705408,0.0007405426,0.0001261597,0.0001443896,0.001437687,9.966967e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009480573,"about_ca_system_score_gemma":0.001034729,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003869819,"about_ca_topic_score_gemma":0.001719356,"domain_scores_codex":[0.9976009,0.0002301578,0.0007470516,0.0006078154,0.0003439944,0.0004701294],"domain_scores_gemma":[0.9961127,0.0008347515,0.0005558805,0.001971722,0.0004547167,0.00007025107],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.05359428,0.0003719262,0.01356523,0.001052183,0.005209707,0.00003405659,0.01293802,0.00007696559,0.05098967,0.00001794543,0.7856518,0.0764982],"study_design_scores_gemma":[0.01845757,0.0007833975,0.422423,0.005819391,0.000491975,0.0001352543,0.001072678,0.0004499287,0.003769284,0.0009207083,0.5444308,0.001246005],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.06467249,0.06679438,0.00003013513,0.8416619,0.0006316084,0.003848498,0.02215691,0.0001350803,0.00006900874],"genre_scores_gemma":[0.2134944,0.180375,0.001802196,0.5862154,0.001539394,0.006246928,0.002965494,0.0008286432,0.006532629],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.4088578,"threshold_uncertainty_score":0.9997556,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4396900273","doi":"10.1002/cac2.12547","title":"Long‐term survival outcomes and immune checkpoint inhibitor retreatment in patients with advanced cervical cancer treated with camrelizumab plus apatinib in the phase II CLAP study","year":2024,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":14,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CAE (Canada)","funders":"","keywords":"Apatinib; Medicine; Oncology; Cervical cancer; Internal medicine; Overall survival; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.03813081594581162,"gpt":0.3588766162722905,"spread":0.3207458003264789,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001787377,0.0003414688,0.0006560108,0.0002316992,0.0002175061,0.00005518772,0.000343054,0.00007399668,0.0001107618],"category_scores_gemma":[0.00002802583,0.0001855871,0.00007144336,0.001280165,0.0001918385,0.0001528303,0.0001933443,0.0004879127,0.000003235991],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001071275,"about_ca_system_score_gemma":0.0003167828,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005817081,"about_ca_topic_score_gemma":0.02252824,"domain_scores_codex":[0.9980333,0.0002160158,0.0005322366,0.0004487179,0.0004409906,0.0003287448],"domain_scores_gemma":[0.9981623,0.0002688828,0.0001077263,0.001207592,0.0001298051,0.0001236956],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003255424,0.005162072,0.9479083,0.00008874305,0.0004701701,0.00005239557,0.004286186,0.00001827894,0.00001430537,0.00003514921,0.000005482093,0.03870343],"study_design_scores_gemma":[0.04019564,0.004569119,0.9526131,0.0007237283,0.0004917227,0.000003036546,0.0008844027,0.00006183865,0.00006030144,0.000008758258,0.0001717726,0.0002165863],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840896,0.009333777,0.000003538445,0.003068133,0.00009503186,0.002730791,0.0001453299,0.00006447482,0.0004692995],"genre_scores_gemma":[0.9949772,0.00143181,0.00009628836,0.0001458361,0.00003610854,0.002885938,0.0002238128,0.00004531031,0.0001576847],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03848685,"threshold_uncertainty_score":0.9953081,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4410905923","doi":"10.1002/cac2.70036","title":"Simvastatin overcomes the pPCK1‐pLDHA‐SPRINGlac axis‐mediated ferroptosis and chemo‐immunotherapy resistance in AKT‐hyperactivated intrahepatic cholangiocarcinoma","year":2025,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Ferroptosis and cancer prognosis","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"China Postdoctoral Science Foundation; National Natural Science Foundation of China","keywords":"Protein kinase B; Cancer research; PI3K/AKT/mTOR pathway; Gemcitabine; Cancer; Medicine; Biology; Internal medicine; Phosphorylation; Signal transduction; Cell biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02681305955760351,"gpt":0.3202265771922991,"spread":0.2934135176346956,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002757722,0.0002268581,0.0004060436,0.0001927711,0.0003311941,0.00006912209,0.0005762363,0.0001047341,0.0001312901],"category_scores_gemma":[0.0001719957,0.0001789071,0.00008996687,0.001099388,0.0004336991,0.0001339472,0.000209917,0.0005495233,0.000007338621],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003804055,"about_ca_system_score_gemma":0.0003064304,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001577665,"about_ca_topic_score_gemma":0.00301553,"domain_scores_codex":[0.9985533,0.0001928757,0.0004532344,0.0003128849,0.0001862559,0.0003014346],"domain_scores_gemma":[0.9974343,0.0005653397,0.0001393832,0.001621773,0.0001670977,0.00007215067],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000814097,0.0009282333,0.9053975,0.0004151456,0.000811333,0.000005187087,0.007534237,0.00002260329,0.02085321,0.008131073,0.007013897,0.04807353],"study_design_scores_gemma":[0.003039954,0.00006267821,0.9028093,0.0009732897,0.000159592,0.000002605128,0.001635542,0.001037588,0.003578082,0.0003598121,0.08603715,0.0003044591],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8979877,0.04207554,0.00004773978,0.05219723,0.0001129858,0.0009187525,0.00003849025,0.00009860248,0.006522926],"genre_scores_gemma":[0.973454,0.02085201,0.0009804957,0.002906313,0.00002690484,0.0009384166,0.00005058628,0.00003204574,0.0007592511],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07902325,"threshold_uncertainty_score":0.7295619,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2979711603","doi":"10.1186/s40880-019-0405-5","title":"Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study","year":2019,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":13,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Institutes of Health Research","funders":"Renji Hospital; Science and Technology Commission of Shanghai Municipality; Pfizer","keywords":"Sunitinib; Sorafenib; Axitinib; Medicine; Renal cell carcinoma; Oncology; Targeted therapy; Internal medicine; Neoadjuvant therapy; Radiation therapy; Tyrosine-kinase inhibitor; Cancer; Breast cancer; Hepatocellular carcinoma","retraction":null,"screen_n_in":null,"score":{"opus":0.08029438110833828,"gpt":0.3685204662015316,"spread":0.2882260850931934,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.000248243,0.0004852189,0.001404188,0.0002281799,0.0003006314,0.00004075609,0.0005145619,0.0003846446,0.00005860157],"category_scores_gemma":[0.00005958,0.0004255182,0.0001838808,0.0002048047,0.0005753064,0.00006427999,0.0003235266,0.001395938,0.000004328531],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003477452,"about_ca_system_score_gemma":0.0004026316,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001359607,"about_ca_topic_score_gemma":0.0001909485,"domain_scores_codex":[0.9975689,0.0003197706,0.0007693729,0.0006184325,0.0003633428,0.0003601568],"domain_scores_gemma":[0.9952698,0.000907176,0.0006706929,0.002534794,0.0005063027,0.0001112838],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.002552366,0.003516665,0.8086506,0.001028341,0.001639133,0.00005879115,0.01667221,0.000008909942,0.001506499,0.00008566929,0.1570505,0.007230339],"study_design_scores_gemma":[0.01834616,0.006213566,0.8266866,0.0005474722,0.001733885,0.0000269021,0.00200053,0.0001444424,0.001765651,0.00005538919,0.1418519,0.0006275426],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9100972,0.02400179,0.00001397063,0.05445262,0.0001153404,0.007116432,0.0005144417,0.0000477123,0.00364046],"genre_scores_gemma":[0.9847983,0.002593896,0.0005721654,0.008177374,0.0003276388,0.0009762883,0.0009465979,0.0001097503,0.001497965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07470109,"threshold_uncertainty_score":0.9998196,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3092210493","doi":"10.1002/cac2.12101","title":"The prognostic significance of non‐sentinel lymph node metastasis in cutaneous and acral melanoma patients—A multicenter retrospective study","year":2020,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Cutaneous Melanoma Detection and Management","field":"Medicine","cited_by":9,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Brandon Regional Health Authority","funders":"National Natural Science Foundation of China","keywords":"Medicine; Sentinel lymph node; Melanoma; Internal medicine; Oncology; Adjuvant therapy; Proportional hazards model; Retrospective cohort study; Stage (stratigraphy); Lymphovascular invasion; Cancer; Metastasis; Surgery; Breast cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02736989431627381,"gpt":0.2941599558314208,"spread":0.2667900615151471,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00009471254,0.0001192105,0.0002451107,0.00005207924,0.0001698693,0.00002356249,0.0002870235,0.0000256198,0.00002727793],"category_scores_gemma":[0.0002068118,0.00009412401,0.00004804915,0.000309925,0.0001593141,0.00003601714,0.0002750349,0.0001760851,0.000006343318],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001324243,"about_ca_system_score_gemma":0.00004885179,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003280865,"about_ca_topic_score_gemma":0.0003792241,"domain_scores_codex":[0.9989989,0.0001182589,0.0003337463,0.0002139572,0.000179507,0.000155565],"domain_scores_gemma":[0.998747,0.0001470702,0.0001478702,0.0007070811,0.0001659362,0.00008503855],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002088991,0.0005820179,0.9916992,0.00004549131,0.0001735251,0.000009626762,0.002332266,0.00002093505,0.0004903241,0.00003630274,0.0001212287,0.004280207],"study_design_scores_gemma":[0.002151459,0.0002024857,0.9880672,0.0000555731,0.0002520905,0.000005999133,0.002904168,0.00417246,0.0001118701,0.00001059405,0.001958203,0.0001079036],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9914097,0.0005558043,0.00007853698,0.004975581,0.00006766153,0.001592288,0.00002974725,0.00003293227,0.001257756],"genre_scores_gemma":[0.9981596,0.0005966611,0.0003373148,0.0003780162,0.00002193323,0.0003439033,0.00001018355,0.00001699986,0.0001353207],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006749975,"threshold_uncertainty_score":0.3838266,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3207609899","doi":"10.1002/cac2.12223","title":"Licochalcone A suppresses Sp1 expression with potential anti‐myeloma activity","year":2021,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Pharmacological Effects of Natural Compounds","field":"Pharmacology, Toxicology and Pharmaceutics","cited_by":7,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Natural Science Foundation of China","keywords":"Multiple myeloma; Cancer research; Expression (computer science); Chemistry; Biology; Medicine; Internal medicine; Computer science","retraction":null,"screen_n_in":null,"score":{"opus":0.1819406175528442,"gpt":0.464422000164961,"spread":0.2824813826121169,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":["research_integrity"],"category_scores_codex":[0.0003133693,0.0006968366,0.0009012238,0.0001971175,0.001015644,0.0001257396,0.002890993,0.001951443,0.003773911],"category_scores_gemma":[0.00009516729,0.0005876137,0.0002938838,0.0005301348,0.001017307,0.0003138503,0.00159077,0.01042988,0.00009839335],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003298202,"about_ca_system_score_gemma":0.0005273679,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001020347,"about_ca_topic_score_gemma":0.00007126731,"domain_scores_codex":[0.9949186,0.002565681,0.0004229403,0.0008086829,0.0004333125,0.0008507877],"domain_scores_gemma":[0.9946699,0.001860163,0.00051907,0.002212808,0.0004834049,0.0002546409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002044986,0.0003739157,0.0001782699,0.0002462676,0.0005864112,0.0004872164,0.00007171807,0.0002250078,0.1969761,0.00001529562,0.7953517,0.005283525],"study_design_scores_gemma":[0.001417358,0.0001250849,0.0006709687,0.0002488541,0.0007564396,0.0001006556,0.00002113438,0.0006963827,0.06245869,0.00006383971,0.9326786,0.0007619528],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.07643395,0.02116551,0.000139593,0.8898606,0.002499372,0.001552569,0.001094565,0.0005501618,0.006703676],"genre_scores_gemma":[0.6299981,0.007790396,0.0007905542,0.3531661,0.002717682,0.001154753,0.001276005,0.0001213085,0.002985139],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.5535641,"threshold_uncertainty_score":0.9996575,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4281746720","doi":"10.1002/cac2.12314","title":"Cancer diagnosis is one quarter lower than the expected cancer incidence in the first year of COVID‐19 pandemic in Germany: A retrospective register‐based cohort study","year":2022,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Canadian Association of University Research Administrators","funders":"Deutsche Forschungsgemeinschaft","keywords":"Coronavirus disease 2019 (COVID-19); Pandemic; Retrospective cohort study; Incidence (geometry); Quarter (Canadian coin); Cancer; Medicine; 2019-20 coronavirus outbreak; Cohort; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Register (sociolinguistics); Cancer incidence; Internal medicine; Virology; Disease; History; Mathematics","retraction":null,"screen_n_in":null,"score":{"opus":0.1524427599252091,"gpt":0.4369747190569758,"spread":0.2845319591317667,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001093903,0.0003918724,0.0009524005,0.0004179466,0.0004629788,0.00004247559,0.002101863,0.0003304758,0.00260108],"category_scores_gemma":[0.0004075787,0.0002908155,0.0002013009,0.001598976,0.000471341,0.00008904735,0.000390663,0.003853894,0.000004951192],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00592904,"about_ca_system_score_gemma":0.003961005,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.2472614,"about_ca_topic_score_gemma":0.4302875,"domain_scores_codex":[0.9959122,0.001053147,0.0008887244,0.0006336729,0.0009936313,0.0005186552],"domain_scores_gemma":[0.9923867,0.001923915,0.0006788364,0.004589368,0.0003063089,0.0001148512],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0001404286,0.0003777239,0.7434195,0.0002194594,0.0001560672,0.0000324808,0.020458,0.00001749713,0.000001774323,0.000004901413,0.2350927,0.00007946076],"study_design_scores_gemma":[0.001259164,0.0002322728,0.6947008,0.0007233692,0.00031441,0.000003259302,0.002040343,0.00004812927,0.000001208915,0.0000365876,0.3004138,0.0002265838],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.09763259,0.009637274,0.000004958984,0.8862976,0.0002516422,0.004917238,0.0009346121,0.00005251563,0.0002715617],"genre_scores_gemma":[0.6268281,0.01127094,0.000009627453,0.3392278,0.000307398,0.02200785,0.0001037304,0.00005101781,0.0001935322],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.5470698,"threshold_uncertainty_score":0.9999544,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3119084223","doi":"10.1002/cac2.12128","title":"Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors","year":2021,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Crizotinib; Anaplastic lymphoma kinase; Ceritinib; Lung cancer; Medicine; ALK inhibitor; ROS1; Adenocarcinoma; Alectinib; Targeted therapy; Internal medicine; Oncology; Cancer research; Pathology; Cancer; Malignant pleural effusion","retraction":null,"screen_n_in":null,"score":{"opus":0.04499332222414623,"gpt":0.3792784071182471,"spread":0.3342850848941008,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00010661,0.0001453633,0.000251337,0.00007452358,0.00031426,0.00003435554,0.0001670599,0.00006813619,0.00006632959],"category_scores_gemma":[0.0001332109,0.0001078465,0.00005452003,0.0003427532,0.0001622911,0.0000936459,0.0002697011,0.0001944662,0.000006207174],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001660263,"about_ca_system_score_gemma":0.0006166318,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001622182,"about_ca_topic_score_gemma":0.0003410239,"domain_scores_codex":[0.9989955,0.0001024969,0.0003008562,0.0002946548,0.0001345022,0.000171971],"domain_scores_gemma":[0.9977634,0.000273793,0.00008660478,0.001241947,0.0004047912,0.0002294439],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0002762905,0.0009038295,0.9714231,0.00002753568,0.0003625774,0.000004975068,0.001957554,0.000004440233,0.0005041186,0.0004333801,0.002873056,0.02122909],"study_design_scores_gemma":[0.003110313,0.0002178406,0.9517696,0.0003042733,0.00031446,0.00001205584,0.0005023933,0.000107698,0.0001750953,0.00002230136,0.04332166,0.0001423118],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9688347,0.007175147,0.000847398,0.01799539,0.0002452489,0.0008919874,0.0004515004,0.00006803458,0.003490568],"genre_scores_gemma":[0.9903066,0.001100416,0.005276659,0.001775849,0.00007820554,0.0002208823,0.0002386543,0.00002846394,0.0009742313],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04044861,"threshold_uncertainty_score":0.4397852,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4317830464","doi":"10.1002/cac2.12401","title":"A nanotherapeutic strategy to target drug‐tolerant cells and overcome EGFR tyrosine kinase inhibitor resistance in lung cancer","year":2023,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University; FujiFilm VisualSonics (Canada)","funders":"National Cancer Institute; National Institutes of Health","keywords":"Cancer research; Epidermal growth factor receptor; Lung cancer; Population; Receptor tyrosine kinase; Drug resistance; AXL receptor tyrosine kinase; Medicine; Cancer; Chemistry; Pharmacology; Biology; Internal medicine; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.06163173093804817,"gpt":0.387045254619975,"spread":0.3254135236819268,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003406675,0.0003541159,0.0009682797,0.0004342744,0.0002308433,0.0000598808,0.0006777869,0.0004466899,0.0003470953],"category_scores_gemma":[0.00005288811,0.0003381572,0.00009291467,0.0008006881,0.0004092072,0.00006795357,0.0003413549,0.001997158,0.00004730762],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001174197,"about_ca_system_score_gemma":0.001523652,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.003766957,"about_ca_topic_score_gemma":0.009685245,"domain_scores_codex":[0.9975377,0.0003265883,0.0005862056,0.0005317214,0.0003889659,0.0006287749],"domain_scores_gemma":[0.9968028,0.0006883088,0.0001601562,0.001929991,0.0002296592,0.0001890629],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001742749,0.000136829,0.01290364,0.001271646,0.0002926085,0.0002316939,0.001645525,0.00002182431,0.002163749,0.0001239652,0.9803194,0.0007148489],"study_design_scores_gemma":[0.001816896,0.00009355383,0.0139261,0.003266949,0.0003614525,0.000006915797,0.0001273816,0.001016726,0.0001334795,0.000232555,0.9785615,0.0004564996],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.02126772,0.07661872,0.0000324357,0.8950556,0.0003471112,0.00235993,0.000957247,0.000116033,0.003245207],"genre_scores_gemma":[0.07081818,0.0991107,0.007917574,0.6311876,0.003317503,0.01241546,0.00115879,0.0005139682,0.1735602],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.263868,"threshold_uncertainty_score":0.999907,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406030350","doi":"10.1002/cac2.12650","title":"A strong internal promoter drives massive expression of YEATS‐domain devoid <i>MLLT3</i> transcripts in HSC and most lethal AML","year":2025,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Acute Myeloid Leukemia Research","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"Institut National Du Cancer; Association Laurette Fugain; Ministère de la Santé; Fondation ARC pour la Recherche sur le Cancer; Fondation de France; Institut National de la Santé et de la Recherche Médicale; Agence Nationale de la Recherche","keywords":"RNA polymerase II; Transcription factor; Transactivation; Molecular biology; Cell biology; Transcription (linguistics); Biology; Chemistry; Promoter; Gene expression; Genetics; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.03057785634176597,"gpt":0.3543113829083722,"spread":0.3237335265666063,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001685487,0.0001136473,0.0002570255,0.0002151512,0.00008651872,0.00001529313,0.0004742939,0.00008667965,0.00005867145],"category_scores_gemma":[0.00006725472,0.0001025568,0.00004449436,0.0003442646,0.0004036433,0.0001029541,0.0003352213,0.0005334118,0.000001775249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003017428,"about_ca_system_score_gemma":0.000482024,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006159957,"about_ca_topic_score_gemma":0.0007407632,"domain_scores_codex":[0.998997,0.0001700852,0.0002981997,0.0001910872,0.0001470862,0.0001964809],"domain_scores_gemma":[0.9986604,0.0001481513,0.00006766067,0.0009212754,0.0001256058,0.00007686263],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0006032182,0.0005168442,0.09641122,0.0004870059,0.0001868069,0.00002413077,0.0111624,0.00002388868,0.8568508,0.004388277,0.005709969,0.02363541],"study_design_scores_gemma":[0.02624825,0.0007915847,0.3927009,0.0152675,0.0004508959,0.00008436997,0.01974658,0.008255318,0.4384224,0.004993828,0.09201188,0.001026434],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9560666,0.006142591,0.00222137,0.01751391,0.00006703017,0.0009132651,0.0000811684,0.0000326674,0.01696141],"genre_scores_gemma":[0.9914172,0.00147171,0.005630355,0.0002222872,0.00001961084,0.0002486758,0.00003429069,0.00001470802,0.0009411442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4184284,"threshold_uncertainty_score":0.4182145,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2978677248","doi":"10.1186/s40880-019-0397-1","title":"A novel prognostic prediction tool for postoperative recurrence in patients with stage II/III colon cancer","year":2019,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Circular RNAs in diseases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":3,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Hospital; University of Toronto; Sunnybrook Health Science Centre","funders":"","keywords":"Colorectal cancer; Stage (stratigraphy); Disease; Cancer; Oncology; Medicine; Internal medicine; Adjuvant; Bioinformatics; Adjuvant chemotherapy; Biomarker; Adjuvant therapy; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.02352228968308826,"gpt":0.2956936177384594,"spread":0.2721713280553711,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00006805732,0.0002546147,0.0002474831,0.00007161155,0.0001981284,0.00003334431,0.0008104664,0.0003508872,0.00002614559],"category_scores_gemma":[0.0001274981,0.0002490909,0.000079721,0.0001445559,0.0001752855,0.00001166626,0.0003450359,0.0005016398,0.00000167636],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002343282,"about_ca_system_score_gemma":0.0007532941,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002325074,"about_ca_topic_score_gemma":0.0008855618,"domain_scores_codex":[0.9987425,0.0000773587,0.0002754922,0.0004668029,0.000170027,0.0002678575],"domain_scores_gemma":[0.9976194,0.0000656445,0.0002322929,0.001594179,0.000460903,0.00002761477],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0005878207,0.0009205871,0.2327888,0.0004221458,0.0006412104,0.000001016954,0.0004918167,0.0009797427,0.005639692,0.00003819607,0.7544178,0.003071071],"study_design_scores_gemma":[0.002682147,0.0005047565,0.03220434,0.0005864702,0.000172826,6.355875e-7,0.00002099467,0.0001860776,0.0004598704,0.000004818062,0.9626924,0.0004846169],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6579542,0.02364936,0.003763522,0.227235,0.002042629,0.02151535,0.06280428,0.0001241415,0.0009115232],"genre_scores_gemma":[0.6648464,0.005336143,0.003699244,0.2144861,0.001588865,0.03193029,0.06934871,0.0003517237,0.008412567],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2082746,"threshold_uncertainty_score":0.9999961,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4387930994","doi":"10.1002/cac2.12496","title":"Dynamics and cytokinic regulation of immune cell infiltration in genetically engineered mouse models of pancreatic cancer dictate the sensitivity to immunotherapy","year":2023,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"","keywords":"Immunophenotyping; Immune system; Cancer research; Biology; KRAS; CD8; Tumor microenvironment; CD80; Immunotherapy; Pancreatic cancer; Flow cytometry; Cancer; Immunology; Cytotoxic T cell; Colorectal cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04858681729706475,"gpt":0.3398288874732581,"spread":0.2912420701761934,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006081274,0.0002052505,0.0007923461,0.0002859994,0.0000877798,0.00001073902,0.0003504444,0.0003438843,0.0000265453],"category_scores_gemma":[0.00009996602,0.0001702452,0.00009661876,0.0005302367,0.0004127543,0.00005076193,0.0001807709,0.0009190742,0.000002386899],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003534118,"about_ca_system_score_gemma":0.0006290105,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.005236943,"about_ca_topic_score_gemma":0.002215446,"domain_scores_codex":[0.9980337,0.0004291221,0.0007483603,0.0002259414,0.0003072676,0.0002556098],"domain_scores_gemma":[0.9964187,0.001183972,0.0003061894,0.001685655,0.0003577485,0.00004776617],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"simulation_or_modeling","study_design_scores_codex":[0.003075172,0.001970516,0.1594539,0.01020441,0.006170719,0.00006903503,0.03884568,0.05797493,0.5792111,0.005855629,0.084552,0.05261698],"study_design_scores_gemma":[0.003136158,0.000465975,0.3255913,0.002066114,0.001098009,0.00001483659,0.0004554626,0.6586974,0.003639493,0.001402547,0.002882952,0.0005497253],"study_design_candidate":"simulation_or_modeling","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5330026,0.007939937,0.004643831,0.4492487,0.00009646173,0.003067562,0.000832144,0.00005830678,0.001110522],"genre_scores_gemma":[0.9342119,0.0488004,0.002743289,0.009588979,0.0001405812,0.001057341,0.0007172677,0.00009298082,0.002647294],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6007225,"threshold_uncertainty_score":0.7916726,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404666579","doi":"10.1002/cac2.12632","title":"PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer","year":2024,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Protein Tyrosine Phosphatases","field":"Biochemistry, Genetics and Molecular Biology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Breakthrough Breast Cancer","keywords":"Trastuzumab; Breast cancer; Biomarker; Oncology; Internal medicine; Acquired resistance; Medicine; Cancer; Cancer research; Chemistry; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01540405219052927,"gpt":0.2892659662646147,"spread":0.2738619140740854,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.00008428995,0.0004113099,0.0004398809,0.0001302775,0.0001762029,0.00005379791,0.0005320709,0.0004583968,0.0000338167],"category_scores_gemma":[0.00001331084,0.0004173772,0.0001963299,0.0002207601,0.0003785858,0.00001613877,0.0002514624,0.0003051502,0.000001184282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005006909,"about_ca_system_score_gemma":0.0004056739,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001843129,"about_ca_topic_score_gemma":0.002614797,"domain_scores_codex":[0.9982474,0.0001108477,0.0005012811,0.0006526331,0.0001393979,0.0003483719],"domain_scores_gemma":[0.9981052,0.00004565295,0.0002973678,0.001288799,0.0002115531,0.00005139182],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005283199,0.001322673,0.004186965,0.006128111,0.005966094,0.0001012577,0.0044641,0.0002453625,0.2344154,0.0007343334,0.7044235,0.03272901],"study_design_scores_gemma":[0.006045884,0.0005102954,0.0511466,0.004331056,0.001615147,0.000105258,0.0002351192,0.0004123574,0.541288,0.001464944,0.3906594,0.00218595],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.09357148,0.5368848,0.0002257306,0.3249049,0.0003437336,0.003307936,0.04054189,0.00005415133,0.0001653811],"genre_scores_gemma":[0.9419988,0.03680922,0.001300281,0.007654944,0.0005751747,0.003612051,0.005227034,0.0001754048,0.002647026],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8484274,"threshold_uncertainty_score":0.9998278,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4393231250","doi":"10.1002/cac2.12540","title":"Immune cell pair ratio captured by imaging mass cytometry has superior predictive value for prognosis of non‐small cell lung cancer than cell fraction and density","year":2024,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"National Institutes of Health; Cancer Prevention and Research Institute of Texas","keywords":"Mass cytometry; Lung cancer; Predictive value; Immune system; Cell; Flow cytometry; Medicine; Oncology; Pathology; Internal medicine; Chemistry; Immunology; Phenotype","retraction":null,"screen_n_in":null,"score":{"opus":0.01658592197096139,"gpt":0.2655287443334488,"spread":0.2489428223624874,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.0003865373,0.0007301756,0.001057399,0.0003789604,0.0008013161,0.0001216299,0.0015095,0.001291037,0.000182146],"category_scores_gemma":[0.00003095936,0.0007696991,0.0004077936,0.0004285284,0.001085028,0.00021588,0.0006872542,0.003237397,0.0000235155],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000925014,"about_ca_system_score_gemma":0.001017004,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004328123,"about_ca_topic_score_gemma":0.0001632924,"domain_scores_codex":[0.9967254,0.0005132979,0.0009650426,0.0009326289,0.0001233628,0.0007402029],"domain_scores_gemma":[0.9954669,0.000837313,0.0008556932,0.002205244,0.0005921937,0.0000425917],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008864528,0.0001340036,0.00396831,0.001870888,0.0005439768,0.000002336287,0.001679703,0.00003563367,0.4535181,0.000002393725,0.5378422,0.0003138137],"study_design_scores_gemma":[0.001439295,0.00008772276,0.000484798,0.0006429533,0.001846301,0.000006650052,0.0005507957,0.001080797,0.4854218,0.00003152282,0.5077012,0.0007061495],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.01127527,0.8017215,0.01461342,0.1496009,0.005574024,0.006094461,0.009054232,0.000303796,0.001762384],"genre_scores_gemma":[0.9027327,0.03401152,0.002744862,0.02387511,0.0007370592,0.00936259,0.007803736,0.0004771137,0.01825533],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8914574,"threshold_uncertainty_score":0.9994754,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3133444826","doi":"10.1002/cac2.12151","title":"An integrated genetic‐epigenetic analysis shed light on the mechanisms linking coronavirus disease 2019 (COVID‐19) and cancer","year":2021,"lang":"en","type":"letter","venue":"Cancer Communications","topic":"COVID-19 and healthcare impacts","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Children's Hospital; Genome British Columbia; University of British Columbia","funders":"","keywords":"Biostatistics; Library science; Columbia university; Epidemiology; Medicine; History; Geography; Sociology; Media studies; Pathology","retraction":null,"screen_n_in":null,"score":{"opus":0.1737411189530755,"gpt":0.4479511603154512,"spread":0.2742100413623757,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002718353,0.0004530954,0.0007614409,0.0004179873,0.0007679085,0.0001556896,0.001067165,0.0004740862,0.001312592],"category_scores_gemma":[0.0002608736,0.0003418187,0.0002838043,0.001138236,0.0002446833,0.00004998679,0.0002871254,0.002242848,0.00001458988],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001161367,"about_ca_system_score_gemma":0.004969399,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.01591126,"about_ca_topic_score_gemma":0.01436407,"domain_scores_codex":[0.997024,0.0007731359,0.0005429903,0.0006895161,0.000479525,0.0004908463],"domain_scores_gemma":[0.9928892,0.0007131497,0.0003285435,0.004909841,0.0004286188,0.0007306446],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008778802,0.00127538,0.05343575,0.00428283,0.01491089,0.00113373,0.012137,0.003625519,0.00276785,0.002204357,0.6005946,0.3027542],"study_design_scores_gemma":[0.0004621996,0.0001126836,0.03185167,0.0007451252,0.004801836,0.00000515744,0.0001341437,0.002613287,0.00004887867,0.0004414502,0.9583493,0.0004343125],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"commentary","genre_gemma":"commentary","genre_scores_codex":[0.001759724,0.06323739,0.002349789,0.9299974,0.0002385211,0.001029488,0.001179566,0.0001096545,0.00009845319],"genre_scores_gemma":[0.07766333,0.07506385,0.00089876,0.8396934,0.0008053466,0.0009923215,0.00346099,0.0001050814,0.001316879],"genre_candidate":"commentary","genre_consensus":"commentary","teacher_disagreement_score":0.3577546,"threshold_uncertainty_score":0.9999034,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4413942153","doi":"10.1002/cac2.70058","title":"Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by <i>UGT1A1</i> status in patients with locally advanced rectal cancer: 5‐year update of the CinClare trial","year":2025,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"CAE (Canada)","funders":"Key Research and Development Program of Zhejiang Province; National Health Commission of the People's Republic of China; National Natural Science Foundation of China","keywords":"Capecitabine; Irinotecan; Colorectal cancer; Medicine; Oncology; Internal medicine; Chemoradiotherapy; Neoadjuvant therapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.009827375372114715,"gpt":0.2905353230981026,"spread":0.2807079477259879,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00004921075,0.0001749199,0.0004262825,0.00005963619,0.0001721861,0.00001094456,0.0002375079,0.00004293754,0.0000290063],"category_scores_gemma":[0.00001768283,0.0001064364,0.00003690547,0.0005130229,0.0003435605,0.00005755762,0.000136487,0.0002023783,1.476154e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004812737,"about_ca_system_score_gemma":0.0005140855,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002696018,"about_ca_topic_score_gemma":0.01099235,"domain_scores_codex":[0.99905,0.00005607796,0.000276837,0.0002244156,0.0001823054,0.0002103505],"domain_scores_gemma":[0.9986478,0.00004862401,0.0001479131,0.0008602094,0.0002394674,0.00005596203],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0354596,0.001046683,0.8508255,0.0001038762,0.0006542874,9.474899e-7,0.00114535,0.00008792421,0.0003313082,0.0001628313,0.002608525,0.1075731],"study_design_scores_gemma":[0.1633588,0.002414565,0.7799422,0.00148589,0.0004265434,0.000001173375,0.0004944918,0.0001136954,0.001552081,0.00003896075,0.04981935,0.0003523166],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.974811,0.01380414,0.00002087463,0.007468494,0.00008426332,0.001922526,0.0002749299,0.00002249075,0.001591264],"genre_scores_gemma":[0.9872999,0.01027075,0.000675633,0.0005836362,0.00001277947,0.0007860946,0.00005120059,0.0000201074,0.0002998958],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1278992,"threshold_uncertainty_score":0.6133987,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4406471500","doi":"10.1002/cac2.12661","title":"Bioequivalence of alternative pembrolizumab dosing regimens: current practice and future perspectives","year":2025,"lang":"en","type":"article","venue":"Cancer Communications","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Bioequivalence; Dosing; Pembrolizumab; Medicine; Medical physics; Psychology; Pharmacology; Internal medicine; Pharmacokinetics; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.03932492012326258,"gpt":0.4011608327392284,"spread":0.3618359126159658,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001294696,0.00008836461,0.0001635478,0.00008577974,0.0001453744,0.00001410796,0.0002311909,0.00003520553,0.00003415883],"category_scores_gemma":[0.00006562781,0.00007959626,0.0000541363,0.0003371703,0.0004217841,0.0001244333,0.0001283166,0.0002023632,6.270992e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001845663,"about_ca_system_score_gemma":0.0002659881,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003662595,"about_ca_topic_score_gemma":0.00003592938,"domain_scores_codex":[0.9993739,0.00008820642,0.0001885368,0.0001549307,0.00009937794,0.00009502281],"domain_scores_gemma":[0.9985255,0.0001779721,0.0001455891,0.0008131248,0.0003076152,0.00003021061],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004446347,0.001320015,0.004704945,0.0006974073,0.00170148,0.000002480319,0.02992824,0.000004324231,0.0251926,0.1018125,0.00856057,0.8216292],"study_design_scores_gemma":[0.003741357,0.0001543457,0.01721484,0.001365382,0.0005074248,0.00002381506,0.0193943,0.0003440806,0.002946949,0.000519808,0.9536049,0.000182813],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"empirical","genre_scores_codex":[0.03511933,0.8645803,0.0003592654,0.07968725,0.0004339705,0.000608171,0.00005077178,0.00005085508,0.01911008],"genre_scores_gemma":[0.6054515,0.3918733,0.001887313,0.0004003489,0.00009332086,0.00007604025,0.000007537749,0.000007571094,0.0002030382],"genre_candidate":"review","genre_consensus":null,"teacher_disagreement_score":0.9450443,"threshold_uncertainty_score":0.3245841,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4404133614","doi":"10.1002/cac2.12624","title":"FOXO1 or not FOXO1: that is the question","year":2024,"lang":"en","type":"article","venue":"Cancer Communications","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Canadian Nautical Research Society","funders":"Ligue Contre le Cancer; Bristol-Myers Squibb","keywords":"FOXO1; Cytotoxic T cell; Granzyme B; Biology; Cell biology; Transcription factor; Cancer research; Chemistry; In vitro; Biochemistry; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.2035524097820991,"gpt":0.4773397007046023,"spread":0.2737872909225032,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003503861,0.00009369826,0.0001246791,0.00007918862,0.0002558666,0.00008792768,0.0006015767,0.00005994051,0.006164646],"category_scores_gemma":[0.00005847021,0.00005798424,0.00009655617,0.0004246638,0.0002498872,0.00008136124,0.0002235675,0.0004927338,0.0002390888],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002604993,"about_ca_system_score_gemma":0.0004160817,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007038311,"about_ca_topic_score_gemma":0.0008049785,"domain_scores_codex":[0.9991277,0.0001280084,0.0001421924,0.0001648848,0.0002564409,0.0001807106],"domain_scores_gemma":[0.9971877,0.0004924726,0.00002371722,0.002112621,0.0001083893,0.00007513339],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004971682,0.0002121412,0.001982505,0.0002872447,0.0007048007,0.00001747047,0.00867568,0.000007761113,0.05125808,0.02497344,0.2147713,0.6966124],"study_design_scores_gemma":[0.0002610677,0.00005629676,0.002859802,0.0002881256,0.0001129901,0.00002757193,0.0002922692,0.002810557,0.005565992,0.0004405243,0.9872038,0.00008101641],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"commentary","genre_gemma":"empirical","genre_scores_codex":[0.02197826,0.07610897,0.001110286,0.7760637,0.0009587687,0.00248695,0.0002064698,0.0007390058,0.1203475],"genre_scores_gemma":[0.8744871,0.02822454,0.0005960853,0.004587065,0.0002628853,0.0006848912,0.00004972994,0.0000460169,0.09106169],"genre_candidate":"empirical","genre_consensus":null,"teacher_disagreement_score":0.8525088,"threshold_uncertainty_score":0.9947438,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}